Patients can safely be switched onto ‘biosimilar’ medicines in place of the biologic medicines those biosimilars are based on without that reducing treatment effectiveness, the European Medicines Agency (EMA) and national medicines regulators across Europe have said.
We understand Legal Issues in Asia